Prospective Comparison of Attenuation Imaging and Controlled Attenuation Parameter for Liver Steatosis Diagnosis in Patients With Nonalcoholic Fatty Liver Disease and Type 2 Diabetes

被引：8

作者：

Burgio, Marco Dioguardi ^{[1
,2
,9
]}

Castera, Laurent ^{[3
]}

Oufighou, Mehdi ^{[1
]}

Rautou, Pierre-Emmanuel ^{[2
,4
]}

Paradis, Valerie ^{[2
,5
]}

Bedossa, Pierre ^{[5
]}

Sartoris, Riccardo ^{[1
]}

Ronot, Maxime ^{[1
,2
]}

Bodard, Sylvain ^{[6
,7
]}

Garteiser, Philippe ^{[2
]}

Van Beers, Bernard ^{[1
,2
]}

Valla, Dominique ^{[2
,4
]}

Vilgrain, Valerie ^{[1
]}

Correas, Jean Michel ^{[6
,7
,8
]}

机构：

[1] Hop Beaujon, Dept Radiol, AP HP Nord, Clichy, France

[2] Univ Paris Cite, Ctr Rech inflammat, INSERM, Paris, France

[3] Hosp Beaujon, AP HP, Dept Hepatol, Paris, France

[4] Hop Beaujon, Ctr Reference Malad Vasc Foie, Serv Hepatol, Serv Hepatol,DMU DIGEST,FILFOIE,ERN,RARE,LIVER, Clichy, France

[5] Hop Beaujon, Dept Pathol, AP HP Nord, Clichy, France

[6] Necker Univ Hosp, Dept Adult Radiol, AP HP, Paris, France

[7] Univ Paris Cite, Paris, France

[8] Sorbonne Univ, CNRS, INSERM, Lab Imagerie Biomed, Paris, France

[9] Hosp Beaujon, 100 Blvd Gen Leclerc, F-92110 Clichy, France

来源：

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY | 2024年 / 22卷 / 05期

关键词：

Fatty Liver; Nonalcoholic; Steatohepatitis; Ultrasonography; HEPATIC STEATOSIS; ACCURACY;

D O I：

10.1016/j.cgh.2023.11.034

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

BACKGROUND & AIMS: Similarly to the controlled attenuation parameter (CAP), the ultrasound -based attenuation imaging (ATI) can quantify hepatic steatosis. We prospectively compared the performance of ATI and CAP for the diagnosis of hepatic steatosis in patients with type 2 diabetes and nonalcoholic fatty liver disease using histology and magnetic resonance imaging -proton density fat fraction (MRI-PDFF) as references. METHODS: Patients underwent ATI and CAP measurement, MRI, and biopsy on the same day. Steatosis was classified as S0, S1, S2, and S3 on histology (< 5%, 5%-33%, 33%-66%, and > 66%, respectively) while the thresholds of 6.4%, 17.4%, and 22.1%, respectively, were used for MRI-PDFF. The area under the curve (AUC) of ATI and CAP was compared using a DeLong test. RESULTS: Steatosis could be evaluated in 191 and 187 patients with MRI-PDFF and liver biopsy, respectively. For MRI-PDFF steatosis, the AUC of ATI and CAP were 0.86 (95% confidence interval [CI], 0.81-0.91) vs 0.69 (95% CI, 0.62-0.75) for S0 vs S1-S3 (P = .02) and 0.71 (95% CI, 0.64-0.77) vs 0.69 (95% CI, 0.61-0.75) for S0-S1 vs S2-S3 (P = .60), respectively. For histological steatosis, the AUC of ATI and CAP were 0.92 (95% CI, 0.87-0.95) vs 0.95 (95% CI, 0.91-0.98) for S0 vs S1-S3 (P = .64) and 0.79 (95% CI, 0.72-0.84) vs 0.76 (95% CI, 0.69-0.82) for S0-S1 vs S2-S3 (P = .61), respectively. CONCLUSION: ATI may be used as an alternative to CAP for the diagnosis and quantification of steatosis, in patients with type 2 diabetes and nonalcoholic fatty liver disease.

引用

页码：1005 / 1013

页数：9

共 22 条

[1] Noninvasive assessment of hepatic steatosis using a pathologic reference standard: comparison of CT, MRI, and US-based techniques [J].